Change in Director / Key Managerial Personnel

Nature of change: Retirement and subsequent appointment of Senior Management Personnel.

Retirement Details:

  • Mr. Jeffrey Hampton, President and COO of Piramal Critical Care, will retire from the services of the Company
  • Effective from close of business hours on 27th November, 2026
  • Will cease to be Senior Management Personnel (SMP) of the Company from this date

Appointment Details:

  • Mr. Brian Guy appointed as President and COO of Piramal Critical Care
  • Appointed as Senior Management Personnel (SMP) of the Company
  • Effective from 19th October, 2026
  • Appointment approved by the Board of Directors on 30th September, 2026
  • Based on recommendation of the Nomination and Remuneration Committee

Profile of Mr. Brian Guy:

  • Seasoned pharmaceutical industry executive with over 25 years of experience
  • Currently serves as President & Chief Commercial Officer of Breckenridge Pharmaceutical, Inc. (subsidiary of Towa Pharmaceutical Co., Ltd.)
  • Held full U.S. P&L responsibility at Breckenridge Pharmaceutical since 2018
  • Extensive experience in business leadership, commercial operations, strategy execution, and enterprise management
  • Experience in driving business growth, portfolio development, strategic partnerships, and organizational transformation
  • Led expansion of specialty and institutional pharmaceutical businesses
  • Managed global partner networks across multiple countries
  • Played key role in corporate transactions, including sale of Breckenridge Pharmaceutical to Towa Pharmaceutical in 2020
  • Prior experience as Director – Business Development at Aveva Drug Delivery Systems, Inc.

Educational Qualifications:

  • MBA from University of Dayton
  • Master of Science in Administration from Central Michigan University
  • Bachelor of Science in Psychology from Wright State University

Additional Information:

  • Mr. Brian Guy is not related to any Director of the Company
  • The retirement and appointment represent a change in leadership for the Company's Complex Hospital Generics business
  • Mr. Guy is expected to leverage his experience to drive accelerated growth and expansion of this business segment

Key Financial or Operational Approvals

No financial or operational approvals beyond the management change were disclosed in this filing.

Strategic or Business Context

The disclosure indicates that Mr. Guy will focus on driving accelerated growth and expansion of the Company's Complex Hospital Generics business. The appointment is positioned to support the company's purpose of 'Doing well and Doing good' through delivering innovative solutions that serve consumers.

Any Other Material Information

  • The disclosure is made pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
  • Mr. Maneesh Sharma, Company Secretary & Compliance Officer, signed and submitted the disclosure